ArticleHaematologica2015

Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide.

Inger S Nijhof et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.